The meta-analysis, published in the American Journal of Cardiology, explored data from six different randomized trials. 

Hospitals in California, Illinois and New York performed especially well, according to the outcomes-based rankings. 

The new guidance was designed to help clinicians provide high-quality care before, during and after TAVR procedures. 

A new feasibility study focused on additional patient populations is also in the works.

The Sapien 3 prosthesis continues to impress, though researchers must continue to monitor its performance as time goes on.

More research on long-term outcomes is still needed before TAVR can be recommended for such patients across the board.

Some high-risk patients died during the delay, the research team reported. 

Patients who received TAVR and PCI experienced lower rates of mortality and fewer major bleeding events than those treated with SAVR and CABG. 

The study focused on more than 1,400 TAVR patients treated from August 2007 to June 2018. 

Overall, the team behind the study noted a survival rate of 82.1% after 15 years. 

“The findings of this study will influence shared decision-making between chronic kidney disease patients and the heart team,” one specialist observed. 

According to Medtronic, its Intrepid TTVR system helps meet a “large, unmet clinical need.”